Sirolimus in combination with FTY720: analysis of urinary and serum parameters.
Lopes
C T
CT
Nephrology Division, Department of Medicine, São Paulo, Brazil.
Pletiskaitz
T M F
TM
de Franco
M F
MF
Cordeiro
J A
JA
Bueno
V
V
D000818:Animals; D003404:Creatinine / Q000097:blood* / Q000652:urine; D004231:Diuresis / Q000187:drug effects; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D016030:Kidney Transplantation / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011409:Propylene Glycols / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D011507:Proteinuria; D020123:Sirolimus / Q000494:pharmacology* / Q000627:therapeutic use; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D003404:Creatinine; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine; D020123:Sirolimus